redos trial: optimizing regorafenib dosing in metastatic colorectal cancer
Published 5 years ago • 331 plays • Length 5:53Download video MP4
Download video MP3
Similar videos
-
7:08
the regorafenib dose optimization study
-
3:53
regorafenib in colorectal cancer: optimizing the dose
-
8:14
optimizing treatment with regorafenib in metastic colorectal cancer
-
8:47
colorectal cancer: dosing strategies with regorafenib
-
1:36
optimal dosing of regorafenib in colorectal cancer
-
10:02
role of the multikinase inhibitor regorafenib in metastatic colorectal cancer
-
2:27
dr. bekaii-saab on the redos study in metastatic colorectal cancer
-
8:26
regorafenib in advanced colorectal cancer: dosing strategies
-
1:30
dr. nancy l. lewis discusses the correct trial for regorafenib in metastatic colorectal cancer
-
5:32
colorectal cancer: regorafenib patient selection and dosing
-
11:36
panitumumab, regorafenib, and ziv-aflibercept in metastatic colorectal cancer
-
4:40
sequencing and dosing for refractory colon cancer
-
3:54
colorectal cancer: patient follow-up with regorafenib
-
5:25
second-line and salvage treatment of metastatic colorectal cancer
-
1:04
dr. randall holcombe discusses regorafenib for metastatic colorectal cancer
-
2:08
dr. becerra discusses regorafenib dosing in metastatic crc
-
0:58
dr. kim reviews studies investigating regorafenib in mcrc
-
9:34
regorafenib in colorectal cancer
-
11:24
managing toxicities associated with regorafenib